NLRP3 and metabolic dysfunction-associated steatotic liver disease: On the other hand, there is enough current theoretical conjecture to support the use of molecular compounds targeting the NLRP3 inflammasome for MASLD individuals, and randomized clinical trials are urgently warranted.